30 results about "Antiarrhythmic agent" patented technology

The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent.

The invention relates to a composition and method for increasing blood pressure, including a low pain or analgesic state or hypotensive anaesthesia in a subject that has suffered a life threatening hypotension or shock or reducing hypofusion in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic.

This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and / or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ.

In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and / or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and / or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.

The invention provides a pyrrocoline formylmethyl p-methane sulfonamide phenylethylamine derivative having the structural general formula as shown in the specification and its officinal salt, wherein R1 represents CH3, COCH3, CH2C6H5, COC6H5, CH2C6H4-Cl-p, CH2C6H4CH3-p, CH2C6H4OCH3-p, CH2C6H3OCH2O-3, 4, CH2C6H3(OCH3)2-3, 4 or C6H11; R2 represents H or SO2CH3; and R3 represents SO2CH3. The invention also provides an application of the above pyrrocoline formylmethyl p-methane sulfonamide phenylethylamine derivative and its officinal salt in the preparation of medicines for treating cardiovascular disease. By the adoption of the medicine provided by the invention, side-effect generally existing in III antiarrhythmic drugs is overcome, patient compliance with drugs is raised, and the risk brought by drug interaction is reduced.

The invention relates to a new use of cardiocyte M3 receptor and IKM3 for screening drugs to treat cardiac arrhythmias. The method of screening drugs using cardiocyte M3 receptor and IKM3 as the target has advantages of high accuracy, strong specificity, and simple operation. The drugs screened by means of cardiocyte M3 receptor and IKM3 has high specificity, and can obviously decrease the adverse reactions, promote the curative effect.

This invention relates to benzopyran derivatives of the formula (I) wherein, R<1 >and R<2 >represent each independently a C1-6alkyl group, etc, R<3 >represents a hydroxyl group, etc, R<4 >represents a hydrogen atom, etc, R<6 >represents a hydrogen atom, R<7 >represents a hydrogen atom, etc, X is absent, or represents C=O, etc, R<8 >represents a hydrogen atom, a C1-6alkyl group, etc, R<9 >represents a hydrogen atom or a nitro group, when R<9 >represents a nitro group, Y represents a C4-8alkylene group, -(CH2)m-CR<11>R<12>-(CH2)n- or -(CH2)o-O-(CH2)p-, R<5 >represents a hydrogen atom, an amino group, a C1-6alkoxy group, a C1-6alkylthio group, a C1-6alkylamino group, a C1-6 alkoxycarbonylamino group, etc, or pharmaceutically acceptable salts thereof. These compounds are useful as an antiarrhythmic agent.

The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.

A system and method for evaluating effects of an antiarrhythmic agent. The system includes: an action potential measurement unit for measuring a cardiac action potential of a patient; an ion channel characteristics determination unit for determining ion channel characteristics of the patient using the cardiac action potential; and an antiarrhythmic agent effect evaluation unit for simulating a treatment effect of an antiarrhythmic agent by reflecting characteristics of the antiarrhythmic agent on the determined ion channel characteristics of the patient. The system can conveniently determine the patient's ion channel characteristics by measuring the cardiac action potential of the patient, thereby preventing the risk of gathering cardiomyocytes of the patient. In addition, the system can simulate a treatment effect of an antiarrhythmic agent that usually exhibits a different effect and a different level of safety depending on an individual's ion channel characteristics, without being directly applied to the patient.